<DOC>
	<DOC>NCT00168012</DOC>
	<brief_summary>The purpose of this study is to demonstrate the effect of IVIG-F10 on the prevention of serious bacterial infections in patients with primary immunodeficiency. As secondary endpoints the rate of overall infections, the tolerability and safety of IVIG-F10 are studied.</brief_summary>
	<brief_title>Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>IgG Deficiency</mesh_term>
	<mesh_term>Immunoglobulins, Intravenous</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Key Patients with primary immunodeficiency Regular IVIG therapy for at least 6 months prior to receiving IVIGF10 Key Allergic reactions to immunoglobulins or other blood products Steroids (oral and parenteral, daily â‰¥0.15 mg of prednisone equivalent/kg/day History of cardiac insufficiency Epilepsia</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Immunoglobulin intravenous</keyword>
	<keyword>Agammaglobulinemia</keyword>
	<keyword>Hypogammaglobulinemia</keyword>
	<keyword>Common variable immunodeficiency</keyword>
	<keyword>Immunoglobulin G</keyword>
	<keyword>Children</keyword>
</DOC>